EpiPen Price Hike Costs The Pentagon Millions

The stock price of Mylan is soaring, but the pharmaceutical company might not be out of the woods yet. After a winter of bad headlines, Congressional testimony and agreements to pay back millions to the US government, the Pentagon is looking at how much Mylan has been overcharging since 2008.